Study guide

9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders

Key Takeaways Explain This Topic AI

First-trimester bleeding differential diagnosis centers on spontaneous abortion subtypes, ectopic pregnancy, and molar gestation; evaluation mandates quantitative serum beta-hCG, transvaginal ultrasonography, and maternal Rh(D) status determination.

Spontaneous abortion is categorized by cervical os status and tissue passage: threatened (closed os, cardiac activity present), inevitable (open os, cramps, no tissue passed), incomplete (open os, partial tissue passage), complete (closed os, all tissue expelled), and missed (closed os, embryonic demise).

More than 95% of ectopic pregnancies are tubal, most in the ampulla (~70%); diagnosis combines serial hCG and TVUS (an empty uterus above the discriminatory level, which ACOG says may be as high as 3,500 mIU/mL) with an abnormal hCG trajectory (<35% rise over 48 hours).

Medical management of ectopic pregnancy with single-dose intramuscular methotrexate (50 mg/m² BSA) requires hemodynamic stability, unruptured mass <3.5 cm, absent embryonic cardiac activity, baseline hCG <5,000 mIU/mL, and normal hepatic/renal function, monitored on Days 4 and 7.

Late-pregnancy bleeding mandates immediate ultrasound before digital pelvic examination: placenta previa manifests with painless bright red bleeding (digital exam strictly contraindicated), placental abruption presents with painful dark bleeding and uterine tetany, and vasa previa features painless bleeding with acute fetal exsanguination at membrane rupture.

Last updated: October 2026

First-Trimester Bleeding: Differential Diagnosis of Spontaneous Abortion

First-trimester vaginal bleeding complicates approximately 20% to 25% of all clinically recognized pregnancies. Initial clinical assessment requires vital sign stabilization, speculum examination to identify the bleeding source and cervical os status, quantitative serum beta-hCG, transvaginal ultrasonography (TVUS), and maternal ABO and Rh(D) blood typing.

Spontaneous Abortion Subtypes

Early pregnancy loss refers to the non-viable intrauterine pregnancy up to 12 6/7 weeks gestation. Clinical subtyping dictates therapeutic intervention:

Subtype Cervical Os Status Products of Conception (POC) Clinical Manifestations & Sonographic Findings

Threatened Abortion Closed internal os Intact in utero Vaginal bleeding with or without mild cramping. TVUS confirms viable intrauterine pregnancy with detectable embryonic cardiac activity.

Inevitable Abortion Open internal os Intact in utero (unexpelled) Vaginal bleeding and moderate-to-severe cramping. Cervical effacement/dilation present; gestational sac or membranes visible at or bulging into external os.

Incomplete Abortion Open internal os Partial passage of POC Heavy vaginal bleeding, severe cramping, and passage of tissue fragments. TVUS demonstrates thick, irregular, heterogeneous retained tissue within the cavity.

Complete Abortion Closed internal os Complete expulsion of all POC History of heavy bleeding and tissue passage, now subsided into light spotting. TVUS shows an empty uterine cavity with a thin, regular endometrial stripe.

Missed Abortion Closed internal os Retained non-viable embryo Minimal spotting or asymptomatic; cessation of pregnancy symptoms. TVUS demonstrates crown-rump length (CRL) ≥7 mm without cardiac activity or mean sac diameter ≥25 mm without an embryo.

Septic Abortion Open or closed os Retained infected POC Intrauterine infection presenting with maternal fever, chills, tachycardia, malodorous purulent cervical discharge, uterine/pelvic peritonitis, and leukocytosis.

Management of Early Pregnancy Loss

Threatened Abortion: Expectant management and reassurance. Bed rest and pelvic rest are frequently advised, though evidence demonstrates bed rest does not alter clinical trajectory.

Incomplete, Inevitable, or Missed Abortion:

Expectant Management: Safe for stable patients in the first trimester; complete expulsion occurs within 2 to 4 weeks in 70% to 80% of cases.

Medical Management: Misoprostol 800 mcg vaginally (or 600 mcg sublingually), with a repeat dose (no sooner than 3 hours and typically within 7 days) if expulsion is incomplete (ACOG Practice Bulletin 200). Pre-treatment with oral mifepristone 200 mg 24 hours prior significantly increases complete expulsion rates.

Surgical Management: Manual vacuum aspiration (MVA) or electric suction curettage; indicated for heavy hemorrhage, hemodynamic instability, intrauterine infection, or patient preference.

Septic Abortion: Medical emergency. Prompt initiation of broad-spectrum intravenous antibiotics (e.g., ampicillin, gentamicin, and clindamycin) followed by immediate surgical uterine evacuation.

Rh Prophylaxis: For pregnancy loss or abortion before 12 weeks , ACOG's 2024 Clinical Practice Update suggests forgoing routine Rh testing and Rho(D) immune globulin (it may be offered on request). At 12 weeks or later , give 300 mcg Rho(D) immune globulin to unsensitized Rh(D)-negative patients.

Ectopic Pregnancy: Diagnostic Triad & Algorithms

Ectopic pregnancy occurs when a blastocyst implants outside the endometrial cavity. Over 95% implant in the fallopian tube (ampulla ~70%, isthmus ~12%, fimbriae ~11%, and interstitium/cornua ~2–3%). Cornual/interstitial pregnancies carry a catastrophic risk of fatal maternal hemorrhage at 8 to 12 weeks gestation due to extensive myometrial vascularity.

Clinical Presentation & Risk Factors

Classic Triad: Amenorrhea (or abnormal menses), unilateral pelvic or lower abdominal pain, and vaginal bleeding.

Rupture Signs: Sudden severe sharp pelvic pain, syncope, hypotension, involuntary guarding/rebound, or referred shoulder pain (Kehr sign) resulting from diaphragmatic irritation by hemoperitoneum.

Major Risk Factors: Prior ectopic pregnancy (highest risk; ~10% recurrence), history of pelvic inflammatory disease (PID) or salpingitis, prior tubal reconstructive surgery or tubal ligation, conception with an intrauterine device (IUD) in situ, assisted reproductive technology (ART), and cigarette smoking.

Diagnostic Algorithm: The Discriminatory Zone

Combining serial quantitative serum beta-hCG and transvaginal ultrasonography (TVUS) is the diagnostic cornerstone:

Discriminatory Zone: The serum beta-hCG concentration above which a normal intrauterine gestational sac with a yolk sac should be reliably visualized on TVUS. Many centers use 1,500 to 2,000 mIU/mL , but ACOG notes it may be as high as 3,500 mIU/mL ; one hCG value should not prompt treatment of a possibly viable pregnancy.

Diagnostic Interpretation:

If serum beta-hCG is above the discriminatory level and TVUS shows an empty uterine cavity , an ectopic or nonviable pregnancy is strongly suspected.

If serum beta-hCG is <1,500 mIU/mL and TVUS is non-diagnostic (pregnancy of unknown location [PUL]), obtain serial beta-hCG measurements 48 hours apart.

hCG Doubling Kinetics: A normal viable intrauterine pregnancy exhibits a rise of at least 35% to 50% over 48 hours . A subnormal rise, plateau, or erratic decline confirms an abnormal gestation (ectopic vs. failing IUP).

  • Medical vs. Surgical Management of Ectopic Pregnancy
  • Medical Therapy: Methotrexate Protocol

Methotrexate (MTX) is a folic acid antagonist that halts dihydrofolate reductase, arresting DNA synthesis and cellular proliferation in actively dividing trophoblastic cells.

Inclusion Criteria for MTX:

Hemodynamically stable with no peritoneal signs.

Unruptured ectopic mass <3.5 cm in greatest dimension on ultrasound.

Absence of embryonic cardiac activity on sonography.

Baseline serum beta-hCG concentration <5,000 mIU/mL (higher levels correlate with steep failure rates).

Normal baseline hepatic enzymes (AST/ALT), renal function (creatinine), and complete blood count.

Patient willing and able to comply with mandatory post-treatment surveillance.

Absolute Contraindications: Hemodynamic instability, ruptured ectopic pregnancy, intrauterine pregnancy (heterotopic), renal dysfunction, hepatic disease, active pulmonary disease, severe anemia or thrombocytopenia, active peptic ulcer disease, or breastfeeding.

Dosing Protocol (Single-Dose): 50 mg/m² body surface area (BSA) administered as an intramuscular injection on Day 1 .

Post-Methotrexate Surveillance

Measure serum beta-hCG on Day 1 , Day 4 , and Day 7 .

A transient increase in beta-hCG between Day 1 and Day 4 is expected as trophoblastic tissue lyses.

Compare Day 4 and Day 7 levels: Successful response requires a ≥15% decrease in serum beta-hCG between Day 4 and Day 7 .

If beta-hCG decreases ≥15%: Follow weekly beta-hCG levels until undetectable (<5 mIU/mL).

If beta-hCG fails to decrease <15%: Administer a second dose of MTX (50 mg/m²) on Day 7 or proceed to surgical intervention.

Patient Counseling: Avoid folic acid supplements (blunts MTX efficacy), NSAIDs (impairs renal clearance of MTX), vigorous exercise/intercourse (prevents mechanical rupture), and sun exposure (photosensitivity).

Surgical Therapy

Indicated for hemodynamically unstable patients, ruptured ectopic pregnancy, contraindications to or failure of methotrexate, ectopic mass ≥3.5 cm, detectable fetal cardiac motion, or concurrent desire for permanent sterilization.

Laparoscopic Salpingectomy: Complete surgical excision of the involved fallopian tube. Preferred procedure in cases of severe tubal destruction, extensive hemorrhage, or completed childbearing.

Laparoscopic Salpingostomy: Linear incision along the antimesenteric border of the tube, gentle hydrodissection/removal of the ectopic trophoblast, allowing secondary intention closure. Indicated when the contralateral fallopian tube is absent or damaged to preserve future fertility; requires serial weekly beta-hCG monitoring to exclude persistent trophoblastic tissue.

Late-Pregnancy Bleeding: Placental Disorders & Emergencies

Second- and third-trimester vaginal bleeding requires urgent evaluation. The primary clinical imperative is to determine placental localization via ultrasound BEFORE any digital pelvic or cervical examination is performed .

Disorder Bleeding Character Pain / Uterine Tone Fetal Heart Rate Tracing Hallmark Features & Management

Placenta Previa Painless , bright red blood Soft, non-tender, relaxed uterus Typically normal / reassuring Placenta covers internal os. Digital exam strictly contraindicated . Cesarean delivery at 36 0/7–37 6/7 weeks.

Placental Abruption Painful , dark red blood (or concealed) Hypertonic, tetanic , rigid, tender uterus Late decelerations, bradycardia, loss of variability Premature placental detachment. Maternal DIC, consumptive coagulopathy. Emergency delivery if unstable.

Vasa Previa Painless , bright red blood Soft, non-tender uterus Abrupt, severe bradycardia or sinusoidal pattern Fetal vessels traverse membranes over os. Membrane rupture causes fetal exsanguination. Emergency cesarean.

Uterine Rupture Variable vaginal bleeding Sudden, severe, tearing pain ; cessation of contractions Prolonged, severe bradycardia / terminal deceleration Disruption of uterine wall (prior cesarean/TOLAC). Loss of fetal station . Immediate laparotomy.

Placenta Previa

Definition: Implantation of the placenta over or immediately adjacent to the internal cervical os. Current terminology uses placenta previa (placenta covers the internal os) and low-lying placenta (edge within 2 cm of the os); older terms such as marginal or partial previa are no longer used.

Presentation: Sudden episodes of painless, bright red vaginal bleeding in the late second or third trimester.

Mandatory Rule: NEVER perform a digital cervical examination in a patient with third-trimester bleeding until transabdominal or transvaginal ultrasound has completely excluded placenta previa. Digital palpation can disrupt the placental cotyledons, triggering catastrophic, exsanguinating hemorrhage.

Management: Pelvic rest, avoidance of strenuous activity, and scheduled cesarean delivery at 36 0/7 to 37 6/7 weeks gestation .

Placental Abruption (Abruptio Placentae)

Pathophysiology: Premature separation of a normally implanted placenta from the uterine myometrium before delivery, leading to decidual hemorrhage and hematoma formation.

Risk Factors: Maternal chronic hypertension or preeclampsia (most common), blunt abdominal trauma (motor vehicle accident, falls, intimate partner violence), cocaine or amphetamine abuse, cigarette smoking, rapid uterine decompression (e.g., following membrane rupture with polyhydramnios), and prior abruption.

Presentation: Painful, dark red vaginal bleeding (concealed behind retroplacental clot in 20% of cases), sudden severe abdominal or lower back pain, frequent high-frequency contractions progressing to uterine hypertonicity (woody/rigid uterus) , and uterine tenderness.

Complications: Consumptive coagulopathy with disseminated intravascular coagulation (DIC) driven by systemic release of decidual tissue factor, maternal hypovolemic shock, fetal hypoxia, and stillbirth.